Negin Pournoori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Negin Pournoori has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Austin Donnelly Evans
Bioengineering and Nanomedicine Group, Faculty of Medicine and Health Technologies, Tampere University, 33720, Tampere, Finland
1 shared publication Emmi Saksala
Bioengineering and Nanomedicine Group, Faculty of Medicine and Health Technologies, Tampere University, 33720, Tampere, Finland
1 shared publicationHamid Delavari H.
Department of Materials Engineering Tarbiat Modares University P.O. Box 14115-143 TEHRAN IRAN
1 shared publicationMohammad Ali Oghabian
Department of Medical Physics and Biomedical Engineering School of Medicine Tehran University of Medical Sciences Tehran Iran
1 shared publication- Oommen P. Varghese
Translational Chemical Biology Group Science for Life Laboratory Division of Macromolecular Chemistry Department of Chemistry‐Ångstrom Laboratory Uppsala University Uppsala Sweden
1 shared publication Rasoul Irajirad
Finetech in Medicine Research Center Iran University of Medical Sciences Tehran Iran
1 shared publication
Latest Publications
- Open Access
- 22 May 2024
- Published by Elsevier in Biomaterials
- Vol. 309, 122629
Glycosaminoglycans' for brain health: Harnessing glycosaminoglycan based biomaterials for treating central nervous system diseases and in-vitro modeling
- 22 May 2024
- Published by Elsevier in Biomaterials
- Vol. 309, 122629
Open AccessGlycosaminoglycans' for brain health: Harnessing glycosaminoglycan based biomaterials for treating central nervous system diseases and in-vitro modeling
- 5 April 2022
- Published by Wiley in ChemMedChem
- Vol. 17 (11) , e202100708
Magnetic Resonance Imaging of Tumor‐Infiltrating Lymphocytes by Anti‐CD3‐Conjugated Iron Oxide Nanoparticles
Immune checkpoint blockade, considered a revolutionary approach in cancer treatment, is only effective in patients with high tumor‐infiltrating lymphocytes (TILs). This work aimed to investigate the feasibility of targeted contrast agent (CA) based on dextran‐coated superparamagnetic iron oxide nanoparticles (SPIONs‐DEX) for TILs detection by magnetic resonance imaging (MRI) studies. To do so, we synthesized an MRI CA by conjugating SPIONs‐DEX to an anti‐CD3 monoclonal antibody via cyanogen bromide as a cross‐linker. In vitro assessments demonstrated the higher labeling efficiency of the developed CA to CD3+ lymphocytes compared to SPIONs‐DEX. In vivo MRI of a xenograft model of CD3+ lymphocytes revealed the significant signal loss after the intravenous injection of the bioconjugate by ∼34 % and 21 % in T2*‐weighted and T2‐weighted images, respectively. The histopathological evaluation of xenograft tumors confirmed the labeling of lymphocytes by the targeted CA. This approach could open up a new horizon in the non‐invasive assessment of TILs to identify patients eligible for immunotherapy.
- 5 April 2022
- Published by Wiley in ChemMedChem
- Vol. 17 (11) , e202100708
Magnetic Resonance Imaging of Tumor‐Infiltrating Lymphocytes by Anti‐CD3‐Conjugated Iron Oxide Nanoparticles
Immune checkpoint blockade, considered a revolutionary approach in cancer treatment, is only effective in patients with high tumor‐infiltrating lymphocytes (TILs). This work aimed to investigate the feasibility of targeted contrast agent (CA) based on dextran‐coated superparamagnetic iron oxide nanoparticles (SPIONs‐DEX) for TILs detection by magnetic resonance imaging (MRI) studies. To do so, we synthesized an MRI CA by conjugating SPIONs‐DEX to an anti‐CD3 monoclonal antibody via cyanogen bromide as a cross‐linker. In vitro assessments demonstrated the higher labeling efficiency of the developed CA to CD3+ lymphocytes compared to SPIONs‐DEX. In vivo MRI of a xenograft model of CD3+ lymphocytes revealed the significant signal loss after the intravenous injection of the bioconjugate by ∼34 % and 21 % in T2*‐weighted and T2‐weighted images, respectively. The histopathological evaluation of xenograft tumors confirmed the labeling of lymphocytes by the targeted CA. This approach could open up a new horizon in the non‐invasive assessment of TILs to identify patients eligible for immunotherapy.